Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT)
Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, Jackisch C, Antolin S, Solbach C, Aftimos P, Huober J, Untch M, Balic M, Reinisch M, Blohmer JU, Concalves A, Rey J, Buechele T, Loibl S (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: KARGER
City/Town: BASEL
Pages Range: 30-30
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
DOI: 10.1016/j.annonc.2022.03.074
Authors with CRIS profile
Involved external institutions
Kantonsspital St.Gallen
Switzerland (CH)
Philipps-Universität Marburg
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Coruña University Hospital / Complexo Hospitalario Universitario A Coruña (CHUAC)
Spain (ES)
Charité - Universitätsmedizin Berlin
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Beaumont Hospital
Ireland (IE)
HELIOS Kliniken
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Technische Universität Dresden
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Institute Paoli-Calmettes
France (FR)
Université libre de Bruxelles (ULB) / Free University of Brussels
Belgium (BE)
Switzerland (CH)
Philipps-Universität Marburg
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Coruña University Hospital / Complexo Hospitalario Universitario A Coruña (CHUAC)
Spain (ES)
Charité - Universitätsmedizin Berlin
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Beaumont Hospital
Ireland (IE)
HELIOS Kliniken
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Technische Universität Dresden
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Institute Paoli-Calmettes
France (FR)
Université libre de Bruxelles (ULB) / Free University of Brussels
Belgium (BE)
How to cite
APA:
Marme, F., Hanusch, C., Furlanetto, J., Morris, P., Link, T., Denkert, C.,... Loibl, S. (2022). Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT). In ONCOLOGY RESEARCH AND TREATMENT (pp. 30-30). BASEL: KARGER.
MLA:
Marme, Frederik, et al. "Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 30-30.
BibTeX: Download